# Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

> **NCT01125189** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 558 (actual)

## Conditions studied

- Hepatitis C Virus

## Interventions

- **DRUG:** Daclatasvir
- **DRUG:** Daclatasvir
- **DRUG:** Placebo
- **DRUG:** peg-interferon alfa-2a
- **DRUG:** ribavirin

## Key facts

- **NCT ID:** NCT01125189
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2012-04
- **Final completion:** 2012-08
- **Target enrollment:** 558 (ACTUAL)
- **Last updated:** 2015-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01125189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01125189, "Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01125189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*